Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $151.00 price target on the stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... [Yahoo! Finance]
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results